ALK and anaplastic large cell lymphoma: For children and adolescents with R/R ALCL, two trials with ALK inhibitors are currently open for recruitment: the post‐marketing trial CRISP with Crizotinib (EudraCT 2015‐005437‐53) and the phase 1/2 study BrigaPED testing brigatinib (NCT04925609).